سعر ماريفانيل 1مجم 50 قرص 2023

Oral vitamin K antagonist anticoagulant tablet containing warfarin 1 mg, packed as 50 tablets (Egyptian directories).

• Prophylaxis and treatment of venous thrombosis and its extension, and pulmonary embolismPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis and treatment of thromboembolic complications of atrial fibrillation and/or cardiac valve replacementPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Reduction in the risk of death, recurrent myocardial infarction and thromboembolic events (stroke, systemic embolisation) after myocardial infarctionPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Serious: haemorrhage, tissue necrosis, calciphylaxis, acute kidney injury, systemic atheroemboli. Other reported: hypersensitivity (urticaria, anaphylaxis), vasculitis, hepatitis and elevated liver enzymes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy, except in pregnant women with mechanical heart valves at high risk of thromboembolism.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Haemorrhagic tendencies or blood dyscrasias; active bleeding or ulceration of the GI, genitourinary or respiratory tract; CNS haemorrhage, cerebral aneurysm, dissecting aorta; pericarditis/pericardial effusion; bacterial endocarditis; malignant hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Recent or planned CNS or eye surgery or traumatic surgery with large open surfaces; spinal puncture or procedures with risk of uncontrollable bleeding; major regional or lumbar block anaesthesia; threatened abortion, eclampsia, pre-eclampsia; unsupervised patients likely to be non-compliant; hypersensitivity to warfarin.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: warfarin can cause major or fatal bleeding; monitor the INR regularly. Drugs, dietary changes and other factors affect the INR.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bleeding risk is higher in the first month and with INR above 4.0, age 65 or over, variable INRs, prior GI bleeding, hypertension, cerebrovascular disease, anaemia, malignancy, trauma, renal impairment and long therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Skin and tissue necrosis or gangrene (uncommon, usually within days of starting), calciphylaxis, acute kidney injury and systemic atheroemboli/cholesterol microemboli can occur; discontinue if necrosis occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Antiplatelets, NSAIDs (e.g. aspirin, ibuprofen, diclofenac), other anticoagulants, SSRIs/SNRIsThese drugs increase bleeding risk with warfarin; monitor closely.DailyMed (U.S. National Library of Medicine)
• CYP2C9, CYP1A2 and CYP3A4 inhibitors and inducersInhibitors can increase and inducers decrease the INR; monitor the INR when starting or stopping them.DailyMed (U.S. National Library of Medicine)
• Botanical products (e.g. garlic, Ginkgo biloba, coenzyme Q10, St John's wort, ginseng)Some botanicals add to bleeding risk (garlic, ginkgo) while others may decrease warfarin effect (coenzyme Q10, St John's wort, ginseng); monitor the INR more often when starting or stopping them.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy except in women with mechanical heart valves at high risk of thromboembolism; warfarin causes a recognised pattern of malformations (warfarin embryopathy), fatal fetal haemorrhage and increased miscarriage and fetal death.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Warfarin was not detected in human milk in a limited study of 15 mothers; weigh benefits and risks and monitor breastfed infants for bruising or bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Warfarin: Inhibits the C1 subunit of vitamin K epoxide reductase (VKORC1), reducing synthesis of vitamin K-dependent clotting factors II, VII, IX and X and proteins C and S (US label).